Study identifier:H8O-US-GWAY
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects with Type 2 Diabetes Mellitus Treated with Metformin
Diabetes Mellitus, Type 2
Phase 3
No
exenatide, rosiglitazone
All
137
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Eli Lilly and Company
This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.
Location
Location
Renton, WA, United States
Location
League City, TX, United States
Location
Cincinatti, OH, United States
Location
San Antonio, TX, United States
Location
San Francisco, CA, United States
Location
Boston, MA, United States
Location
Phoenix, AZ, United States
Location
Bronx, NY, United States
Arms | Assigned Interventions |
---|---|
Experimental: Exenatide Arm | Drug: exenatide subcutaneous injection, 5mcg or 10mcg, twice a day Other Name: Byetta |
Experimental: Exenatide plus Rosiglitazone Arm | Drug: exenatide subcutaneous injection, 5mcg or 10mcg, twice a day Other Name: Byetta Drug: rosiglitazone oral tablet, 2mg or 4mg, twice a day Other Name: Avandia |
Experimental: Rosiglitazone Arm | Drug: rosiglitazone oral tablet, 2mg or 4mg, twice a day Other Name: Avandia |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.